MaaT Pharma S.A.
MAAT.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €2,427 | €1,495 | €1,721 | €850 |
| % Growth | 62.3% | -13.1% | 102.5% | – |
| Cost of Goods Sold | €790 | €1,571 | €537 | €594 |
| Gross Profit | €1,637 | -€76 | €1,184 | €256 |
| % Margin | 67.4% | -5.1% | 68.8% | 30.1% |
| R&D Expenses | €14,778 | €14,607 | €12,695 | €11,201 |
| G&A Expenses | €3,611 | €3,158 | €2,872 | €2,556 |
| SG&A Expenses | €4,102 | €2,885 | €3,180 | €2,665 |
| Sales & Mktg Exp. | €491 | €538 | €308 | €109 |
| Other Operating Expenses | -€2,494 | €0 | -€1,935 | -€2,201 |
| Operating Expenses | €16,386 | €17,492 | €13,940 | €11,665 |
| Operating Income | -€14,749 | -€17,568 | -€12,756 | -€11,409 |
| % Margin | -607.7% | -1,175.1% | -741.2% | -1,342.2% |
| Other Income/Exp. Net | -€336 | -€377 | -€1,720 | €127 |
| Pre-Tax Income | -€15,085 | -€17,945 | -€14,476 | -€11,282 |
| Tax Expense | €0 | -€1,897 | -€1,620 | €0 |
| Net Income | -€15,085 | -€16,048 | -€12,856 | -€11,282 |
| % Margin | -621.5% | -1,073.4% | -747% | -1,327.3% |
| EPS | -1 | -1.15 | -1.05 | -0.97 |
| % Growth | 13% | -9.5% | -8.2% | – |
| EPS Diluted | -1 | -1.15 | -1.05 | -0.97 |
| Weighted Avg Shares Out | 15,112 | 13,978 | 12,195 | 11,599 |
| Weighted Avg Shares Out Dil | 15,112 | 13,978 | 12,195 | 11,599 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €762 |
| Interest Expense | €422 | €616 | €262 | €508 |
| Depreciation & Amortization | €114 | €858 | €117 | €104 |
| EBITDA | -€14,636 | -€16,471 | -€12,639 | -€11,304 |
| % Margin | -603% | -1,101.7% | -734.4% | -1,329.9% |